News ReleaseView printer-friendly version
Quidel to Hold First Quarter 2005 Financial Results Conference Call on May 10
SAN DIEGO--(BUSINESS WIRE)--May 4, 2005--Quidel Corporation (Nasdaq:QDEL), a leading provider of rapid point-of-care diagnostic tests, will release first quarter 2005 financial results after market close on Tuesday, May 10, 2005.
Following the release of the results, Caren L. Mason, president and chief executive officer, and Paul E. Landers, senior vice president and chief financial officer, will host an investment community conference call beginning at 5:00 p.m. ET (2:00 p.m. PT) to discuss those results and to answer questions.
As noted in Quidel's April 27th press release, this conference call was previously scheduled and postponed due to the late-breaking news of the litigation settlement between Quidel and Inverness Medical.
To participate in the live call by telephone, from the U.S., dial (888) 803-7396, or from outside the U.S. dial (706) 634-1052. A live webcast of the call can be accessed at www.quidel.com. The Web site replay will be available for 14 days and the telephone replay will be available for 48 hours by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering reservation number 6063432.
Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), the portfolio currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, Strep A, pregnancy, bacterial vaginosis, infectious mononucleosis, H. pylori and chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential point-of-care applications in the future. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.quidel.com.
CONTACT: Quidel Corporation
Paul E. Landers, 858-552-7962
Senior Vice President & CFO
Lippert/Heilshorn & Associates
Ina McGuinness (firstname.lastname@example.org)
Bruce Voss (email@example.com)
SOURCE: Quidel Corporation